Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis (IPF): A Retrospective, Pooled Analysis from Ascend, Capacity, and Inspire

Kreuter, Michael; Lee, J.S.; Τzouvelekis, Αrgyris; Oldham, Justin M.; Molyneaux, PL; Weycker, Derek; Atwood, Mark; Kirchgaessler, Klaus-Uwe; Maher, TM

doi:10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6207

D13. Ild Prognosis and Biomarkers Ii 2020

DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6207

|View full text |Cite

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis (IPF): A Retrospective, Pooled Analysis from Ascend, Capacity, and Inspire

Michael Kreuter

J.S. Lee

Αrgyris Τzouvelekis

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2022

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We used data pooled from trials of pirfenidone (ASCEND, NCT01366209; CAPACITY Study 004, NCT00287716; and CAPACITY Study 006, NCT00287729) and IFNγ-1b (INSPIRE; NCT00075998) to further explore the association between monocyte count elevation and prognosis in patients with a confirmed diagnosis of IPF. Some of the results of this analysis have been previously reported in the form of an abstract ( 25 ).…”

mentioning

confidence: 88%

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis

Kreuter

Lee

Tzouvelekis

et al. 2021

Am J Respir Crit Care Med

128

102

View full text Add to dashboard Cite

Rationale: There is an urgent need for simple, cost-effective prognostic biomarkers for idiopathic pulmonary fibrosis (IPF); biomarkers that show potential include monocyte count. Objectives: We used pooled data from pirfenidone and IFNγ-1b trials to explore the association between monocyte count and prognosis in patients with IPF. Methods: This retrospective pooled analysis included patients (active and placebo arms) from the following four phase III, randomized, placebo-controlled trials: ASCEND (NCT01366209), CAPACITY (NCT00287729 and NCT00287716), and INSPIRE (NCT00075998). Outcomes included IPF progression (≥10% absolute decline in FVC% predicted, ≥50 m decline in 6-minute-walk distance, or death), all-cause hospitalization, and all-cause mortality over 1 year. The relationship between monocyte count (defined as time-dependent) and outcomes was assessed using bivariate and multivariable models. Measurements and Main Results: This analysis included 2,067 patients stratified by monocyte count (at baseline: <0.60 × 10 9 cells/L [ n = 1,609], 0.60 to <0.95 × 10 9 cells/L [ n = 408], and ≥0.95 × 10 9 cells/L [ n = 50]). In adjusted analyses, a higher proportion of patients with monocyte counts of 0.60 to <0.95 × 10 9 cells/L or ≥0.95 × 10 9 cells/L versus <0.60 × 10 9 cells/L experienced IPF progression ( P = 0.016 and P = 0.002, respectively), all-cause hospitalization ( P = 0.030 and P = 0.003, respectively), and all-cause mortality ( P = 0.005 and P < 0.001, respectively) over 1 year. Change in monocyte count from baseline was not associated with any of the outcomes over 1 year and did not appear to be affected by study treatment. Conclusions: In patients with IPF, elevated monocyte count was associated with increased risks of IPF progression, hospitalization, and mortality. Monocyte count may provide a simple and inexpensive prognostic biomarker in IPF.

show abstract

mentioning

confidence: 88%

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis

Kreuter

Lee

Tzouvelekis

et al. 2021

Am J Respir Crit Care Med

128

102

View full text Add to dashboard Cite

show abstract

“…Amongst these, absolute blood monocyte count seems to be one of the most promising; in individuals with IPF monocyte counts are associated with risk of disease progression and death. Importantly, when it comes to clinical translation of this finding, monocyte count is already easily and cheaply accessible to clinicians as part of a complete blood count (9)(10)(11). With this in mind, here, Kim et al (12) examined the role of monocytes as potential predictors of the occurrence of ILAs and of subsequent ILA progression.…”

mentioning

confidence: 99%

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?

Kreuter

Maher

2022

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Monocyte and macrophage derived myofibroblasts: Is it fate? A review of the current evidence

Vierhout

Ayoub

Naiel

et al. 2021

Wound Repair Regeneration

View full text Add to dashboard Cite

Since the discovery of the myofibroblast over 50 years ago, much has been learned about its role in wound healing and fibrosis. Its origin, however, remains controversial, with a number of progenitor cells being proposed. Macrophage-myofibroblast transition (MMT) is a recent term coined in 2014 that describes the mechanism through which macrophages, derived from circulating monocytes originating in the bone marrow, transformed into myofibroblasts and contributed to kidney fibrosis.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis (IPF): A Retrospective, Pooled Analysis from Ascend, Capacity, and Inspire

Cited by 4 publications

References 0 publications

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?

Monocyte and macrophage derived myofibroblasts: Is it fate? A review of the current evidence

Contact Info

Product

Resources

About